Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Skin Microbiota

NCT07583121 | Not Yet Recruiting

• 1 other identifier: COS-PBP-03
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This exploratory study aims to investigate the prebiotic potential of daily application of an omega-3 serum and cream to skin affected by eczema. The study will also collect data on any potential adverse effects of the products. Ten subjects will be enrolled in the study and will receive the same treatment for fourteen days. Their baseline condition before treatment will serve as a control for the effects observed after treatment on the targeted eczema area. A second area of eczema treated with the patient's usual skincare routine will also serve as a control.

Conditions

Eczema

Keywords

Skin hydration; Skin inflammation

Outcome Measures

Primary Outcomes (1)

• To determine whether topical treatment with eicosapentaenoic acid monoglycerides can modulate the skin microbiota of eczema-affected skin

  Quantification of the skin microbiota by quantitative Polymerase Chain Reaction (qPCR) targeting the genome of four bacteria (Staphylococcus aureus, Staphylococcus epidermis, Cutibacterium acnes and Streptococcus pyogenes) on both treated and control skin area.

  2 weeks

Secondary Outcomes (1)

• Assessment of potential adverse effects of treatment

  2 weeks

Study Arms (1)

MagOX topic treatment

EXPERIMENTAL

Subjects will receive the daily treatment with MagOX serum and cream

Other: Omega-3 monoglyceride based topical treatment

Interventions

Omega-3 monoglyceride based topical treatment OTHER

Successive daily application of omega-3 monoglyceride based serum and cream on skin with eczema.

MagOX topic treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant aged of at least 18 years old.
• Participant diagnosed with eczema who did not use corticosteroids in the 14 days prior to study day 1;
• Available for the entire duration of the study and willing to participate based on the information provided in the ICF duly read and signed by the latter.
• Participant without intellectual problems likely to limit the validity of consent to participate in the study and compliance with protocol requirements, having the ability to cooperate adequately, understand and observe the instructions of research staff

You may not qualify if:

• None

Sponsors & Collaborators

• SCF Pharma: lead

Study Sites (1)

SCF Pharma

Rimouski, Quebec, G0K 1P0, Canada

Location

MeSH Terms

Conditions

Eczema; Dermatitis

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous

Study Officials

• Samuel Fortin, PhD

  SCF Pharma

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Samuel Fortin, PhD, PhD

CONTACT

418-750-8590; sfortin@scfpharma.com

Anne-Julie Landry, M.Sc, M.Sc

CONTACT

418-360-7480; ajlandry@ircl.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Single Group Assignment This exploratory study includes only one group of ten (10) subjects. All subjects will receive the same treatment, for a similar duration. A skin area with eczema lesions will be identified during the screening visit. Subjects will be asked to apply the serum, then the creams to the targeted area at least once a day for a period of fourteen (14) days. The pre-treatment baseline state will serve as a control for the effects observed following treatment on the targeted area. A second eczema area, treated with the patient's regular hydration routine, will serve as another control for treatment.

Study Record Dates

• First Submitted: April 23, 2026
• First Posted: May 13, 2026
• Study Start: May 4, 2026
• Primary Completion (Estimated): December 4, 2026
• Study Completion (Estimated): December 18, 2026
• Last Updated: May 13, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)